Journey Medical Corp. (DERM)
Drugs • Health Care
May 19, 2026 Journey Medical Corporation to Showcase Expertise at A.G.P.’s Annual Virtual Healthcare Conference Journey Medical Corporation will participate in A.G.P.'s Annual Virtual Healthcare Conference on May 20, 2026. CEO Claude Maraoui will discuss the company's strategic initiatives and product developments in dermatology, highlighting their commitment to investor engagement.
May 06, 2026 Journey Medical Corporation Set to Release Q1 2026 Financial Results Journey Medical Corporation will disclose its Q1 2026 financial results on May 13, 2026. A conference call will follow to discuss performance and strategic plans. Interested participants can join via phone or view the webcast online.
April 21, 2026 Journey Medical Corporation Expands Access to Emrosi™ with New GPO Contract Journey Medical Corporation has secured a major contract with a group purchasing organization, increasing access to its rosacea treatment, Emrosi™, to 85% of U.S. commercial lives. This strategic move aims to improve patient access and drive future growth in the dermatology market.
March 26, 2026 Journey Medical Corp. Reports Strong Revenue Growth in 2025 Annual Report Journey Medical Corp. achieved a revenue of $61.2 million in 2025, marking an 11% increase, mainly due to the successful launch of Emrosi. Despite some competitive pressures, the company's financial performance shows resilience with improved cash flow and balance sheet strength.
March 25, 2026 Journey Medical Corp. Reports Strong 2025 Financial Results and Key Developments Journey Medical Corporation announced a revenue increase to $61.9 million in 2025, primarily due to the launch of Emrosi™, despite challenges with Accutane®. The company also reported improved gross margins and a stronger cash position, indicating a positive outlook for future growth in the dermatology market.
March 18, 2026 Journey Medical Corporation to Announce Year-End 2025 Financial Results Journey Medical Corporation is set to disclose its year-end 2025 financial results on March 25, 2026. Anticipation surrounds the report as investors look for insights into the company's strategic initiatives and market performance in dermatological treatments.
December 10, 2025 Journey Medical Corp. Publishes Promising Clinical Trial Results for Emrosi™ in Leading Dermatology Journal Journey Medical Corporation has released Phase 1 trial results for Emrosi™, showing its efficacy and safety as a treatment for rosacea. The study confirmed no significant impact on the microbiome and a lack of antibiotic resistance, marking a vital step in dermatological treatments.
November 12, 2025 Journey Medical Corporation Reports Strong Q3 2025 Results Journey Medical Corporation reported strong Q3 2025 results with a 21% revenue increase to $17.6 million, driven by Emrosi's successful launch. The company also achieved expanded payer access and clinical validation, positioning it for future growth.
November 12, 2025 Journey Medical Corp. Reports 2025 Q3 Financial Results: A Mixed Bag with Promising Growth Journey Medical Corp. reported a 16% revenue increase in Q3 2025, largely driven by the successful launch of Emrosi. Despite growth, the company faces challenges like competitive pressures and ongoing operational losses.
November 05, 2025 Journey Medical Corporation to Report Third Quarter 2025 Financial Results Journey Medical Corporation is set to release its Q3 2025 financial results on November 12, 2025, followed by a conference call at 4:30 p.m. ET. Stakeholders are eager for insights into the company's performance and future strategies.
October 24, 2025 Journey Medical Corp. Reports Promising Phase 3 Results for Emrosi™ at 2025 Fall Clinical Dermatology Conference Journey Medical Corporation reported encouraging Phase 3 results for Emrosi™ (DFD-29) in treating rosacea, showing superior efficacy over Oracea and placebo. With 62.7% of subjects achieving treatment success, this development positions Emrosi as a potential standard of care in dermatology.
October 08, 2025 Journey Medical Corporation to Engage Investors at October 2025 Conferences Journey Medical Corporation is set to engage investors at two significant conferences in October 2025, focusing on its strategies and growth in dermatology. The company aims to deepen investor relations and showcase its innovative pharmaceutical offerings.
August 12, 2025 Journey Medical Corp. Reports Q2 2025 Results: Emrosi's Impact and Market Challenges Journey Medical Corp. reported mixed Q2 2025 results, driven by the launch of Emrosi for rosacea. Despite revenue growth, the company faces challenges from competition and operational losses.
May 15, 2025 Journey Medical Corp. Reports Q1 2025 Financial Results: A New Chapter with Emrosi™ Journey Medical Corp. reported its Q1 2025 financial results, highlighting a new product launch, Emrosi™, and a slight increase in net revenues despite competitive challenges. The company is positioned for growth as it navigates market dynamics and improves its financial standing.
April 01, 2025 Journey Medical Corporation Announces Leadership Change: Ramsey Alloush Appointed Chief Operating Officer Journey Medical Corporation has promoted Ramsey Alloush to Chief Operating Officer, emphasizing his leadership role in the upcoming launch of Emrosi™. Alloush aims to enhance operational capabilities and deliver significant value to stakeholders as the company navigates the dermatological landscape.
March 27, 2025 Journey Medical Corporation Reports 2024 Annual Results: A Year of Challenges and New Opportunities Journey Medical Corporation's 2024 report reveals an 8% revenue decline amid rising costs and losses. However, the FDA's approval of Emrosi presents new growth opportunities. The company aims to enhance its financial outlook through innovative treatments and strategic marketing.
March 26, 2025 Journey Medical Corporation Announces Full-Year 2024 Financial Results and Key Developments Journey Medical Corporation reported a 29% decline in revenues for 2024, totaling $56.1 million. Despite financial challenges, the company received FDA approval for Emrosi™, aiming to enhance growth and operational efficiency in the dermatology market.
March 24, 2025 Journey Medical Corporation Launches Emrosi™: A New Hope for Rosacea Sufferers Journey Medical Corporation has launched Emrosi™, a modified-release formulation of Minocycline Hydrochloride for treating rosacea. This new treatment offers lower doses and improved clinical outcomes, marking a significant advancement for the millions affected by this condition.
March 19, 2025 Journey Medical Corporation to Reveal Year-End 2024 Financial Results Journey Medical Corporation will disclose its 2024 year-end financial results on March 26, 2025. A conference call will follow to discuss the details, engaging investors and analysts eager for insights into the company's performance.
March 17, 2025 SWOT Analysis of Journey Medical Corp. in 2025 This SWOT analysis of Journey Medical Corp. in 2025 examines its strong dermatology portfolio and experienced management, while addressing weaknesses like market reliance and competition. The article highlights growth opportunities and potential threats, emphasizing the need for strategic navigation in a dynamic industry.
March 12, 2025 Journey Medical Corporation to Showcase Innovations at 37th Annual ROTH Conference Journey Medical Corporation will showcase its innovations at the 37th Annual ROTH Conference from March 16-18, 2025. CEO Claude Maraoui will discuss the company’s strategic vision during a fireside chat and will be available for one-on-one meetings, providing valuable insights for investors.
March 05, 2025 Journey Medical Corp. Publishes Phase 3 Clinical Trial Results for Emrosi™ in JAMA Dermatology Journey Medical Corporation has published significant Phase 3 trial results for Emrosi™ in treating rosacea. The trials demonstrated robust efficacy and safety, positioning Emrosi™ as a potential new standard in dermatological care.
March 04, 2025 Journey Medical Corporation to Showcase Innovative Treatment at AAD Annual Meeting Journey Medical Corporation will showcase Emrosi™, a new FDA-approved treatment for rosacea, at the 2025 AAD Annual Meeting. This innovative oral minocycline offers improved outcomes and safety for patients suffering from this common condition. Join us in Orlando to learn more about this revolutionary product.
November 12, 2024 Journey Medical Corp. Reports Q3 2024 Financial Results: A Mixed Bag with New Opportunities Ahead Journey Medical Corp. reported a mixed Q3 2024 financial performance with a slight revenue decline but strong growth from Qbrexza. The FDA's recent approval of Emrosi offers new growth opportunities as the company navigates a challenging market.
August 13, 2024 Journey Medical Corp. Reports Q2 2024 Results: Analyzing the Financial Landscape Journey Medical Corp. reported mixed Q2 2024 results with a 12% decline in revenue but improved expense management. The submission of a new drug application and strategic financial maneuvers may enhance future prospects.
May 14, 2024 Journey Medical Corp. Reports Q1 2024 Financial Results Journey Medical Corporation's Q1 2024 report showcases a revenue increase of 7% to $13 million, driven by strong product sales. The submission of an NDA for DFD-29 marks a pivotal step for potential market growth, despite facing operational challenges and a net loss of $10.44 million.
March 29, 2024 Journey Medical Corp. 2023 Annual Report: A Year of Transformation and Resilience Journey Medical Corp.'s 2023 Annual Report highlights a 16% decline in revenue to $59.7 million amid strategic cost reductions. Despite operational losses, cash flow improved significantly, showcasing resilience and a focus on future growth in dermatological products.